<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03829514</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00079289</org_study_id>
    <nct_id>NCT03829514</nct_id>
  </id_info>
  <brief_title>Fenofibrate in Type 2 Diabetes</brief_title>
  <official_title>Fenofibrate in Type 2 Diabetes- Novel Biomarkers and Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic complications affecting the eyes, kidneys, and nerves are difficult to arrest once&#xD;
      in progress. Recent evidence that fenofibrate confers a robust yet unexpected benefit in&#xD;
      diabetic retinopathy offers an important translational research opportunity. The&#xD;
      investigator's global proteomic study will provide new clues as to how fenofibrate protects&#xD;
      vulnerable tissues, and will spur discovery of targets for new therapeutic interventions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 4, 2019</start_date>
  <completion_date type="Actual">March 4, 2020</completion_date>
  <primary_completion_date type="Actual">March 4, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in levels of individual plasma proteins, measured as ion current, in proteomic analysis via liquid chromatography-mass spectrometry</measure>
    <time_frame>Baseline through six weeks</time_frame>
    <description>Plasma proteomics enables the study of complex disease processes. Combined with bioinformatics, proteomics is a powerful and unbiased approach that can identify pathways for the multi-organ benefits of fenofibrate, defining new target</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Diabetes Mellitus, Type II</condition>
  <arm_group>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm. Participants will take study medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>40 patients (20 males and 20 females) aged 18-70 years, with type 2 diabetes and triglycerides &gt;150 mg/dL will be recruited. They will have a physical exam and blood draw at visit 1. Participants will receive 160 mg fenofibrate to be taken orally daily for six weeks. They will return for a second visit after 6 weeks and have blood draw as follow up.</description>
    <arm_group_label>Fenofibrate</arm_group_label>
    <other_name>Trilipix</other_name>
    <other_name>Triglide</other_name>
    <other_name>Antara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes of at least one year's duration; stable glycemic control (no more than&#xD;
             1.0% change in HbA1c in the previous six months, but no limit on HbA1c)&#xD;
&#xD;
          -  Triglycerides &gt;150 mg/dL (in the previous six months)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous use of Fenofibrate or other fibrates&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Recent cardiac event or congestive heart failure&#xD;
&#xD;
          -  Active liver disease&#xD;
&#xD;
          -  Significant renal impairment (serum creatinine &gt; 2mg/dl)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 25, 2019</study_first_submitted>
  <study_first_submitted_qc>February 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2019</study_first_posted>
  <disposition_first_submitted>February 17, 2021</disposition_first_submitted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Timothy Lyons</investigator_full_name>
    <investigator_title>Professor and Chief, Division of Endocrinology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 8, 2021</submitted>
    <returned>October 1, 2021</returned>
    <submitted>October 5, 2021</submitted>
    <returned>November 3, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

